TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05991622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined LAI Treatment: Cabenuva and Sublocade
Description: A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
Study: NCT05864222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
Study: NCT05736549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Liposomal Bupivacaine
Description: A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Liposomal Bupivacaine
Description: A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Description: A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study: NCT04306510

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for immunoglobulins
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for inflammatory markers
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for anti-drug antibodies
Description: Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
Study: NCT05227924

Intervention type: DEVICE
Intervention: Total hip arthroplasty (primary or revision)
Description: Total hip arthroplasty with at least one medical device from the SYMBOL range
Study: NCT05736549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Description: A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study: NCT05359861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF388
Description: SRF388 will be administered by intravenous injection (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF388
Description: SRF388 will be administered by intravenous injection (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Azezolizumab will be administered by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Azezolizumab will be administered by IV
Study: NCT05152459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT05359861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Azezolizumab will be administered by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV
Study: NCT05152459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study: NCT06024486

Intervention type: DIAGNOSTIC_TEST
Intervention: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
Description: measurement of serum albumin, fibrinogen and CRP

Intervention type: DIAGNOSTIC_TEST
Intervention: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
Description: measurement of serum albumin, fibrinogen and CRP
Study: NCT04859088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition
Description: Dietary intervention (Liquid food replacement intervention)
Study: NCT05279859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Administered orally
Study: NCT05359861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV
Study: NCT05682742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted Surgery
Description: Subjects scheduled to undergo robotic-assisted surgery
Study: NCT06169553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic injection-related injection treatment
Description: Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
Study: NCT05315479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once daily
Study: NCT01329081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation after fast-track TKA
Description: Six weeks of strength training combined with patient education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation after fast-track TKA
Description: Six to eight weeks of supervised home training
Study: NCT06158802

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient.

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient.
Study: NCT05425901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: endoscopy biopsies (6)
Study: NCT05359861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by IV
Study: NCT03128775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary prevention
Description: Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary prevention + nudge
Description: This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
Study: NCT05837884

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
Study: NCT05425901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: endoscopy biopsies (6)
Study: NCT05022810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Paracetamol Oral Suspension (24 mg/ml)
Description: After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study: NCT06417853

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection
Description: 7.5 mcg Influenza A (H7N9) Injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)
Description: 12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)
Description: 25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection
Description: 7.5 mcg Influenza A (H7N9) with MF59® Injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)
Description: 12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)
Description: 12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)
Description: 20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)
Description: 20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
Study: NCT05022810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol B&I Oral Suspension (24 mg/ml paracetamol)
Description: After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study: NCT04259190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interoceptive exposure
Description: Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
Study: NCT06417853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)
Study: NCT04259190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interoceptive exposure
Description: Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
Study: NCT06417853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microarray Patch Delivery System
Description: Vaccine free Microarray Patch Delivery System (VXS-1219U)
Study: NCT06651489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
Study: NCT06650826

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of anti-platelet factor 4 antibodies in the blood
Description: The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of anti-platelet factor 4 antibodies in the blood
Description: The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of anti-platelet factor 4 antibodies in the blood
Description: The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of anti-platelet factor 4 antibodies in the blood
Description: The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.
Study: NCT06651307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifting with elbow sleeves
Description: Lifting with elbow sleeves
Study: NCT06164886

Intervention type: OTHER
Intervention: Waiting list
Description: patient on the waiting list for scheduled surgical admissions
Study: NCT06198192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
Study: NCT05588401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenPHSat injection (Safety)
Description: Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenPHSat injection (Efficacy)
Description: Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
Study: NCT06198192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy and Balance Exercises
Description: this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
Study: NCT05588401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy (Safety)
Description: Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
Study: NCT06147856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-3210
Description: IV infusion
Study: NCT06650020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronous online learning
Description: Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the traditional offline model of centralized training
Description: The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.